Refractory anemia with excess of blasts 1
ICD-10 D46.21 is a billable code used to indicate a diagnosis of refractory anemia with excess of blasts 1.
Refractory anemia with excess of blasts 1 (RAEB-1) is a subtype of myelodysplastic syndromes (MDS) characterized by ineffective hematopoiesis leading to anemia, and an increased number of myeloblasts in the bone marrow. Patients typically present with symptoms of anemia such as fatigue, pallor, and weakness. The diagnosis is confirmed through bone marrow biopsy, which reveals 5-9% myeloblasts. This condition is classified under neoplasms of uncertain behavior, indicating that while it is not overtly malignant, it has the potential to progress to acute myeloid leukemia (AML). Surveillance is critical as patients with RAEB-1 are at a higher risk for transformation into more aggressive forms of leukemia. Treatment options may include supportive care, growth factors, and in some cases, hematopoietic stem cell transplantation. The prognosis varies based on individual patient factors, including age, overall health, and response to treatment. Regular monitoring of blood counts and clinical symptoms is essential for managing this condition effectively.
Comprehensive documentation of blood counts, bone marrow biopsy results, and treatment plans.
Patients presenting with fatigue and anemia, requiring evaluation of bone marrow.
Ensure accurate reporting of blast percentages and any transformation to acute leukemia.
Detailed treatment plans, response to therapy, and monitoring for progression.
Patients undergoing chemotherapy or stem cell transplantation.
Document any complications or side effects related to treatment.
Used to monitor blood counts in patients with RAEB-1.
Document the reason for the CBC and results.
Hematology specialists should ensure all relevant parameters are included.
The percentage of blasts is crucial for diagnosis and monitoring, as it indicates the severity of the disease and the risk of progression to acute leukemia.
